Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEZS Aeterna Zentaris	$2.78 +5.7%	$3.58	$3.96 ▼ $12.00	$4.99M	1.55	7,305 shs	3,551 shs
HEM Hemostemix	C$0.09 +6.3%	C$0.12	C$0.04 ▼ C$0.43	C$12.39M	0.2	383,060 shs	105,140 shs
IBT IBEX Technologies	C$1.44	C$1.44	C$0.75 ▼ C$1.45	C$35.54M	-0.05	68,888 shs	200 shs
MBX MBX Biosciences	$14.15 +3.8%	$12.43	$4.81 ▼ $27.50	$475.36M	N/A	329,184 shs	227,197 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEZS Aeterna Zentaris	-9.00%	-26.12%	-39.26%	-25.92%	-55.20%
HEM Hemostemix	+2.56%	-11.11%	-40.74%	-27.27%	+77.78%
IBT IBEX Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
MBX MBX Biosciences	+2.33%	+5.25%	+11.81%	+8.95%	+1,362,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HEM Hemostemix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBT IBEX Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	2.5768 of 5 stars	3.5	0.0	0.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEZS Aeterna Zentaris	0.00	N/A	N/A	N/A
HEM Hemostemix	0.00	N/A	N/A	N/A
IBT IBEX Technologies	0.00	N/A	N/A	N/A
MBX MBX Biosciences	3.00	Buy	$37.63	165.90% Upside

Current Analyst Ratings Breakdown

Latest HEM, IBT, MBX, and AEZS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/5/2025	MBX MBX Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEZS Aeterna Zentaris	$2.37M	2.10	N/A	N/A	$14.99 per share	0.19
HEM Hemostemix	N/A	N/A	C$0.01 per share	10.77	C($0.10) per share	N/A
IBT IBEX Technologies	C$5.77M	6.15	C$0.92 per share	1.56	C$0.58 per share	2.48
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEZS Aeterna Zentaris	-$16.55M	-$14.86	N/A	∞	N/A	-760.32%	-83.45%	-45.76%	N/A
HEM Hemostemix	-C$5.00M	-C$0.03	N/A	∞	N/A	N/A	37.07%	-349.24%	N/A
IBT IBEX Technologies	C$3.10M	C$0.12	11.52	∞	N/A	53.78%	21.95%	6.42%	N/A
MBX MBX Biosciences	N/A	-$4.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A
HEM Hemostemix	N/A	N/A	N/A	N/A	N/A
IBT IBEX Technologies	N/A	3.11%	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEZS Aeterna Zentaris	N/A	5.94	5.93
HEM Hemostemix	-55.07	0.04	0.48
IBT IBEX Technologies	11.06	6.24	4.93
MBX MBX Biosciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEZS Aeterna Zentaris	0.73%
HEM Hemostemix	N/A
IBT IBEX Technologies	19.05%
MBX MBX Biosciences	N/A

Insider Ownership

Company	Insider Ownership
AEZS Aeterna Zentaris	0.10%
HEM Hemostemix	10.43%
IBT IBEX Technologies	25.36%
MBX MBX Biosciences	52.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEZS Aeterna Zentaris	20	1.79 million	1.79 million	No Data
HEM Hemostemix	N/A	145.73 million	N/A	Not Optionable
IBT IBEX Technologies	N/A	24.68 million	N/A	Not Optionable
MBX MBX Biosciences	36	33.59 million	N/A	N/A

HEM, IBT, MBX, and AEZS Headlines

Recent News About These Companies

MBX Biosciences Insiders Added US$579.8k Of Stock To Their Holdings

August 20 at 8:26 PM | uk.finance.yahoo.com

MBX Biosciences Submits IND for Once-Monthly Obesity Drug

August 20 at 3:37 AM | finance.yahoo.com

Reviewing MBX Biosciences (MBX) & Its Rivals

August 20 at 2:11 AM | americanbankingnews.com

Jefferies Financial Group Initiates Coverage on MBX Biosciences (NYSE:MBX)

August 17, 2025 | marketbeat.com

Head-To-Head Survey: MBX Biosciences (MBX) versus Its Competitors

August 16, 2025 | americanbankingnews.com

A Glimpse of MBX Biosciences's Earnings Potential

August 14, 2025 | benzinga.com

MBX Biosciences, Inc. (NYSE:MBX) Given Consensus Recommendation of "Buy" by Analysts

August 14, 2025 | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Recommendation of "Buy" from Brokerages

August 13, 2025 | americanbankingnews.com

MBX Biosciences Reports Progress and Financial Stability

August 11, 2025 | tipranks.com

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

August 7, 2025 | globenewswire.com

MBX Biosciences (NYSE:MBX) Coverage Initiated at Mizuho

August 6, 2025 | marketbeat.com

Mizuho Initiates Coverage of MBX Biosciences (MBX) with Outperform Recommendation

August 5, 2025 | msn.com

TD Asset Management Inc Raises Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)

August 5, 2025 | marketbeat.com

MBX Biosciences Inc. (MBX) Stock Price Today - WSJ

August 2, 2025 | wsj.com

MBX Biosciences (NYSE:MBX) Shares Up 15.7% - What's Next?

July 26, 2025 | marketbeat.com

Oppenheimer Initiates Coverage of MBX Biosciences (MBX) with Outperform Recommendation

July 17, 2025 | msn.com

MBX Biosciences Inc Executives - Morningstar

June 25, 2025 | morningstar.comM

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development - Morningstar

June 24, 2025 | morningstar.comM

MBX Biosciences Inc Chart - Morningstar

June 24, 2025 | morningstar.comM

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

June 23, 2025 | globenewswire.com

MBX Biosciences Submits IND for Obesity Treatment

June 16, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HEM, IBT, MBX, and AEZS Company Descriptions

Aeterna Zentaris NASDAQ:AEZS

$2.78 +0.15 (+5.70%)

As of 08/20/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Hemostemix CVE:HEM

C$0.08 +0.01 (+6.25%)

As of 01:22 PM Eastern

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

IBEX Technologies CVE:IBT

C$1.44 0.00 (0.00%)

As of 04/5/2024

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.

MBX Biosciences NYSE:MBX

$14.15 +0.52 (+3.82%)

Closing price 04:00 PM Eastern

Extended Trading

$14.14 -0.01 (-0.04%)

As of 06:48 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time